Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 55 clinical trials
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients

docetaxel plus epirubicin, and docetaxel plus epirubicin plus cyclophosphamide as neoadjuvant chemotherapy for operable premenopausal breast cancer patients, and also to compare the outcomes associated with

  • 0 views
  • 21 Jan, 2021
  • 7 locations
Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

To compare disease-free survival (DFS) rate of adjuvant chemotherapy epirubicin-cyclophosphamide followed by weekly paclitaxel or docetaxel (EC-T), or weekly paclitaxel or docetaxel-carboplatin

epirubicin
breast adenocarcinoma
progesterone receptor
sentinel lymph node biopsy
progesterone
  • 90 views
  • 16 Apr, 2020
  • 27 locations
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

This study is a randomized, single center, phase III clinical trial comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of

trastuzumab
epirubicin
growth factor
triple negative breast cancer
immunohistochemistry
  • 2 views
  • 15 Mar, 2020
  • 1 location
Regimens Comparison for Breast Cancers of Positive Lymph Nodes

To compare the efficacy and safety of EC-T and ET regimen as adjuvant treatment of breast cancer patients with positive lymph nodes

immunostimulant
paclitaxel
epirubicin
cancer surgery
  • 6 views
  • 08 Nov, 2020
  • 1 location
Combination Chemotherapy in Treating Patients With Esophageal Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective in treating esophageal cancer. PURPOSE: Randomized phase …

epirubicin
combination chemotherapy
fluorouracil
esophageal cancer
tumor cells
  • 31 views
  • 07 Nov, 2020
  • 1 location
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. …

her2/neu-positive breast cancer
trastuzumab
aromatase inhibitor
stage iii breast cancer
docetaxel
  • 33 views
  • 07 Nov, 2020
  • 1 location
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

This is a multicenter, international, double-blind randomized Phase III study to evaluate the pathological complete response (pCR) according to Chevalier classification between Fulvestrant and the combination of Fulvestrant plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer. Eligible patients will be assessed upfront using the OncotypeDX …

platelet count
palbociclib
progesterone
goserelin 3.6 mg
calcium
  • 161 views
  • 08 Nov, 2020
  • 1 location
TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Both TC (docetaxel/carboplatin) and EC followed by T (epirubicin/cyclophosphamide followed by docetaxe) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer have been

docetaxel
carboplatin
neutrophil count
carcinoma
platelet count
  • 4 views
  • 08 Nov, 2020
Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Patients with ER+/HER2 breast cancer (presumably the luminal A subtype) could potentially avoid the standard chemotherapy use. Letrozole Plus Low-Dose Metronomic Capecitabine may offer similar efficacy and less toxicity to standard chemotherapy in ER+/HER2 breast cancer patients.

her2/neu-negative breast cancer
docetaxel
capecitabine
epirubicin
cyclophosphamide
  • 8 views
  • 08 Nov, 2020
  • 1 location
A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients

Epirubicin is a common chemotherapy medication used in the treatment of breast cancer. However, chemotherapy dosing is calculated based on people's height and weight, which may not be the most

invasive breast cancer
estrogen
epirubicin
progesterone receptor
estrogen receptor
  • 0 views
  • 08 Nov, 2020
  • 1 location